Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy

Heavily-treatment-experienced people living with human immunodeficiency virus (HTE-PLWH) represent a population with limited therapeutic options and at high-risk of clinical progression, morbidity, and mortality. The development of new drugs and new drug classes for the treatment of HIV-1 infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Muccini, Camilla, Canetti, Diana, Castagna, Antonella, Spagnuolo, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800563/
https://www.ncbi.nlm.nih.gov/pubmed/35115764
http://dx.doi.org/10.2147/DDDT.S273660
_version_ 1784642288338599936
author Muccini, Camilla
Canetti, Diana
Castagna, Antonella
Spagnuolo, Vincenzo
author_facet Muccini, Camilla
Canetti, Diana
Castagna, Antonella
Spagnuolo, Vincenzo
author_sort Muccini, Camilla
collection PubMed
description Heavily-treatment-experienced people living with human immunodeficiency virus (HTE-PLWH) represent a population with limited therapeutic options and at high-risk of clinical progression, morbidity, and mortality. The development of new drugs and new drug classes for the treatment of HIV-1 infection in HTE-PLWH is critical to successfully suppress HIV-1 replication, restore the immune system, and improve quality of life. Fostemsavir is the first attachment inhibitor approved by Food and Drug Administration and European Medicines Agency for the treatment of HIV-1 infection. It is approved in combination with other antiretrovirals, for HTE-PLWH with multi-drug resistant HIV-1 after failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. In this review, we present and discuss the mechanism of action, the pharmacodynamic and pharmacokinetic properties, and the efficacy and safety of fostemsavir as an antiretroviral agent for the treatment of HIV-1 infection.
format Online
Article
Text
id pubmed-8800563
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88005632022-02-02 Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy Muccini, Camilla Canetti, Diana Castagna, Antonella Spagnuolo, Vincenzo Drug Des Devel Ther Review Heavily-treatment-experienced people living with human immunodeficiency virus (HTE-PLWH) represent a population with limited therapeutic options and at high-risk of clinical progression, morbidity, and mortality. The development of new drugs and new drug classes for the treatment of HIV-1 infection in HTE-PLWH is critical to successfully suppress HIV-1 replication, restore the immune system, and improve quality of life. Fostemsavir is the first attachment inhibitor approved by Food and Drug Administration and European Medicines Agency for the treatment of HIV-1 infection. It is approved in combination with other antiretrovirals, for HTE-PLWH with multi-drug resistant HIV-1 after failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. In this review, we present and discuss the mechanism of action, the pharmacodynamic and pharmacokinetic properties, and the efficacy and safety of fostemsavir as an antiretroviral agent for the treatment of HIV-1 infection. Dove 2022-01-25 /pmc/articles/PMC8800563/ /pubmed/35115764 http://dx.doi.org/10.2147/DDDT.S273660 Text en © 2022 Muccini et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Muccini, Camilla
Canetti, Diana
Castagna, Antonella
Spagnuolo, Vincenzo
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
title Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
title_full Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
title_fullStr Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
title_full_unstemmed Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
title_short Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy
title_sort efficacy and safety profile of fostemsavir for the treatment of people with human immunodeficiency virus-1 (hiv-1): current evidence and place in therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800563/
https://www.ncbi.nlm.nih.gov/pubmed/35115764
http://dx.doi.org/10.2147/DDDT.S273660
work_keys_str_mv AT muccinicamilla efficacyandsafetyprofileoffostemsavirforthetreatmentofpeoplewithhumanimmunodeficiencyvirus1hiv1currentevidenceandplaceintherapy
AT canettidiana efficacyandsafetyprofileoffostemsavirforthetreatmentofpeoplewithhumanimmunodeficiencyvirus1hiv1currentevidenceandplaceintherapy
AT castagnaantonella efficacyandsafetyprofileoffostemsavirforthetreatmentofpeoplewithhumanimmunodeficiencyvirus1hiv1currentevidenceandplaceintherapy
AT spagnuolovincenzo efficacyandsafetyprofileoffostemsavirforthetreatmentofpeoplewithhumanimmunodeficiencyvirus1hiv1currentevidenceandplaceintherapy

Ejemplares similares